Contact

Infectious diseases beyond COVID-19 – JPT’s peptide formats in the literature

The past few months have been all about SARS-CoV-2. However, many other infections remain important threats.

Our expertise is in the research and development of highly specific peptides for clinical immunotherapies, vaccines and accompanying immune monitoring. As a result we are constantly introducing new products for well-known infectious diseases such as HIV, TB, CMV, and HBV as well as emerging diseases such as ZIKA, Ebola, MERS, SARS and COVID-19.

Check our overview of infectious disease related products and information!

We proudly present some recent high impact publications describing the use of our reagents for fighting infectious diseases beyond COVID-19. Have a look and let us know how we can collaborate with you in these evolving arenas.

Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or Without Prior Type 16 and/or 18 Exposure
Kai et al, Vaccines (2020)

Modified Alphavirus-Vesiculovirus Hybrid Vaccine Vectors for Homologous Prime-Boost Immunotherapy of Chronic Hepatitis B
Chiale et al, Vaccines (2020)

Evaluation of HIV-1 Neutralizing and Binding Antibodies in Maternal-Infant Transmission in Thailand
Wieczorek et al, Virology (2020)

Safety and Immunogenicity of a Modified Vaccinia Virus Ankara Vector Vaccine Candidate for Middle East Respiratory Syndrome: an Open-Label, Phase 1 Trial
Koch et al, Lancet (2020)

HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular Carcinoma
Zhao et al, Clinical & Experimental Immunology (2020)

Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomized, Placebo-Controlled, Phase 1 Trial
Stephenson et al, The Lancet Infectious Diseases (2020)

Evaluation of Glycoprotein E Subunit and Live Attenuated Varicella‐Zoster Virus Vaccines Formulated with A single‐Strand RNA‐Based Adjuvant
Lee et al, Immunity, Inflammation and Disease (2020)

Women Who Received Varicella Vaccine versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody Levels
Tourtelot et al, Vaccine (2020)

Comparison of Shortened Mosaic HIV-1 Vaccine Schedules: a Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial (IPCAVD010/HPX1002) and a Preclinical Study in Rhesus Monkeys (NHP 17–22)
Stephenson et al, The Lancet HIV (2020)

Identification of Naturally Processed Mumps Virus Epitopes by Mass Spectrometry: Confirmation of Multiple CD8+ T-Cell Responses in Mumps Patients
de Wit et al, The Journal of Infectious Diseases (2020)

HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform
Patelet al, Mol Ther Methods Clin Dev. (2020)

For additional publications, application notes or our publication list for SARS-CoV-2 products please check our website.

Stay in touch and be the first to receive the latest news!